Skip to content
NeuroView Technology
News & Publications
Company2 min read

NeuroView Technology appoints Scott Verner as Chief Executive Officer

An accomplished healthcare executive brings decades of medical device and diagnostics leadership to advance NeuroView toward commercialization.

By NeuroView Communications

The appointment

NeuroView Technology today announced the appointment of Scott Verner as Chief Executive Officer. Verner brings an extensive record of executive leadership across the medical device and diagnostics sectors, with a career defined by scaling innovative healthcare companies from early-stage development to commercial success.

The appointment marks a pivotal moment for NeuroView as the company advances its continuous sub-scalp EEG platform toward FDA De Novo authorization and broader clinical deployment. The board selected Verner for his combination of fundraising acumen, regulatory experience, and demonstrated ability to build high-performing organizations.

Executive background

Verner previously served as Chief Executive Officer of Trividia Health, Nipro Diagnostics / Home Diagnostics, and Applied Sciences Corporation. Across these roles he oversaw multimillion-dollar R&D initiatives and led product launches in partnership with global healthcare companies including Novartis and Allergan.

  • CEO of Trividia Health, scaling diabetes diagnostics with global distribution.
  • CEO of Nipro Diagnostics, leading product development and commercialization strategy.
  • CEO of Applied Sciences Corporation, managing regulatory submissions and licensing.
  • Strategic partnerships with Novartis, Allergan, and other multinational healthcare companies.

“The science behind continuous EEG monitoring is extraordinary. What NeuroView has built puts us in a position to genuinely change how neurological conditions are managed outside the hospital.”

Scott Verner, CEO, NeuroView Technology

Vision for NeuroView

Verner's appointment comes as the company prepares for its pivotal clinical trial and FDA De Novo submission. His experience scaling medical device companies and managing high-stakes fundraising is the leadership NeuroView needs at this stage.

Frequently asked questions

What is Scott Verner's role at NeuroView?

He is the Chief Executive Officer, leading the company through its pivotal clinical trial and FDA De Novo submission toward commercialization.

What has Scott Verner led before?

He was CEO of Trividia Health, Nipro Diagnostics, and Applied Sciences Corporation, with product launches alongside global healthcare companies.

More from NeuroView